Definition of Hypercoagulability, estrogen-associated

1. High Blood Pressure (Hypertension) Slideshow Pictures
2. Take the Salt Quiz!
3. Lowering Blood Pressure Exercise Tips Slideshow Pictures

Hypercoagulability, estrogen-associated: Hypercoagulability (a supranormal tendency for blood to clot) occurs as an occasional but serious side effect of estrogen therapy.

The blood clots in this situation are dose-related, that is, they occur more frequently with higher doses of estrogen.

Estrogen therapy preparations (all of which carry this risk) include:

• esterified estrogens
• esterified estrogens and methyltestosterone
• estradiol
• estrogens (conjugated) and medroxyprogesterone
• estrogens conjugated

The brand names of the estrogen therapy preparations carrying this risk include:

• CLIMARA (estradiol)
• ESTRACE (estradiol)
• ESTRADERM (estradiol)
• ESTRATAB (esterified estrogens)
• ESTRATEST (esterified estrogens and methyltestosterone)
• MENEST (esterified estrogens)
• OGEN (estropipate)
• PREMARIN (estrogens conjugated)
• PREMPHASE (estrogens conjugated and medroxyprogesterone)
• PREMPRO (estrogens conjugated and medroxyprogesterone)

Cigarette smokers on estrogen therapy are at a higher risk than non-smokers for blood clots. Therefore, patients requiring estrogen therapy are strongly encouraged to quit smoking.